See where each patient’s disease is headed, and why.

The Standard Model ingests routine clinical data (records, imaging, pathology and genomics) and forecasts how a patient’s disease will progress and respond to treatment, so drug developers and clinicians can make confident decisions in days, not years. Standard Model Biomedicine builds this JEPA world model of the patient — medical AI trained across genomic, imaging, and longitudinal patient records to forecast clinical outcomes.

Disease doesn't live in one place

The Standard Model reads a patient at every scale — from their cells, to their organs, to their symptoms: the molecular scale (genomics, transcriptomics), the tissue scale (pathology), the organ scale (CT, EKG, EEG, MRI) and the patient scale (EHR, outcomes, adverse events, cognition scores), monitored longitudinally over time.

Patients are multimodal
Patient representations are only as good as the measurements that support them
Every scale matters because they all provide insights into the underlying patient state
Causal inference can only be generalized over time, disease progression, response to therapy, adverse events and comorbidities

Every disease is caused by dysregulation of genes, proteins, tissues and systems. They interact and evolve in response to one another and to changing therapies. The Standard Model decodes these predicted changes through time in latent space, projecting what will happen next, and predicts how that state might be altered by different treatment decisions.

How it works

It fills the knowledge gaps between those scales and builds a complete representation of the patient.

What the Standard Model does

Reduces or replaces real-world data licensing budgets
Identifies patients from routine clinical inputs to advanced haplotype geomapping
Models a digital twin of each patient, or creates a synthetic twin from target criteria
Fine-tunes with your data and works alongside your own models and other leading AI models

The result is a world model of the patient. It delivers more than insights — it delivers answers.

Predicting real-world outcomes before a single patient is dosed

Endpoints

Model overall survival and time-to-next-therapy from predicting trial results.

Enrichment

Flagging patient subtypes, i.e., high-risk or metastasis-free patients, before trial arms are composed.

New modality

Imaging and tissue-based reads (disease staging & classification) as a second lane alongside the RWE track.

Beyond prediction

Standard-of-care in silico comparators across indications, placebo-arm and placebo-response simulation, and post-deployment model monitoring as an ongoing service.

Supported by the pharma experts who built it

Work is performed in partnership in your secure environment.
Rapid deployment, fast insights and robust modeling.
Zero-risk financial model, with built-in opt-ins and opt-outs along the way.

The team is made up of pharma and academic researchers who built the model. Our publications span clinical foundation models, medical imaging, genomics, and federated learning for drug development.

Explore this site

We predict what happens to any patient at any time

Standard Model Biomedicine is based in San Francisco, California. Reach us at info@standardmodel.bio for partnerships, model access, research collaborations, or press.